Premium
Effects of periodontal non‐surgical therapy plus azithromycin on glycemic control in patients with diabetes: a randomized clinical trial
Author(s) -
Botero J. E.,
Yepes F. L.,
Ochoa S. P.,
Hincapie J. P.,
Roldan N.,
Ospina C. A.,
Castrillon C. A.,
Becerra M. A.
Publication year - 2013
Publication title -
journal of periodontal research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.31
H-Index - 83
eISSN - 1600-0765
pISSN - 0022-3484
DOI - 10.1111/jre.12058
Subject(s) - glycemic , medicine , glycated hemoglobin , periodontitis , azithromycin , gastroenterology , diabetes mellitus , randomized controlled trial , placebo , population , dentistry , surgery , type 2 diabetes , endocrinology , pathology , chemistry , antibiotics , biochemistry , alternative medicine , environmental health
Background and Objective Periodontitis may alter the systemic condition in patients with diabetes and hence interfere with glycemic control. The objective of this study was to determine the quantifiable changes in glycated hemoglobin ( H b A 1 C) after periodontal non‐surgical therapy plus azithromycin in a mixed population of patients with poorly controlled diabetes. Materials and Methods One hundred and five patients were randomized to receive non‐surgical therapy plus azythromycin (AZ‐Sca =33), non‐surgical therapy plus placebo ( PB ‐ S ca = 37) and supragingival prophylaxis plus azithromycin ( AZ ‐ P ro = 35). Glycated hemoglobin, glycemia and periodontal parameters were measured at baseline, 3, 6 and 9 mo after treatment. Results Periodontal parameters were improved in the AZ ‐ S ca and PB ‐ S ca groups as compared to the AZ ‐ P ro group. A greater reduction in probing depth was observed in the AZ ‐ S ca as compared to the PB ‐ S ca group. Improvement in clinical attachment level was similar between AZ ‐ S ca and PB ‐ S ca groups. A reduction from 8.0% to 7.2% (∆0.8%; p < 0.05) in H b A 1 C was observed in the AZ ‐ S ca at 9 mo as compared to the PB ‐ S ca group in which the reduction was from 7.9% to 7.6% (∆0.3%). There was no decrease in H b A 1 C in the AZ ‐ P ro group over time. Mean glycemia values decreased from 195 mg/dL to 159.2 mg/dL (∆35.8 mg/dL; p < 0.05) in the AZ ‐ S ca group whereas a decrease from 194 mg/dL to 174.8 mg/dL (∆19.2 mg/dL) in the PB ‐ S ca group at 9 mo was observed. There were no differences between the AZ ‐ S ca and PB ‐ S ca groups for glycemic parameters. No improvement in glycemic values in the AZ ‐ P ro group was observed. Conclusions A modest improvement in glycemic control was detected with a trend towards the use of non‐surgical therapy plus AZ as compared to the placebo.